Simulations Plus, Inc. (NASDAQ:SLP – News), a leading provider of software for pharmaceutical discovery and development, today announced that the pharmacokinetics, dynamics, and metabolism science board at a top three pharmaceutical company named its GastroPlus™ software an “application of choice.” The client also issued a purchase order for additional software licenses at several of its research sites, which expands the number of users in their existing global multi-year software license agreement that began in December 2007.
Ron Creeley, vice president of marketing and sales for Simulations Plus, said: “This is a clear indication of the acceptance of Simulations Plus’ software at the highest scientific and business levels of this top three company. Our achievement of designated vendor status with this company means our software is more widely available to research scientists at the organization, and streamlines purchasing procedures whenever the company obtains products or services from Simulations Plus.”
Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: “As pharmaceutical companies face a significant number of patent expirations in the near future, there is a need to become more aggressive in research and development to fill the pipeline, sometimes with reduced R&D staff. Productivity tools like GastroPlus™, ADMET Predictor™, ClassPharmer™, and DDDPlus™ leverage the expertise of the industry’s scientific teams. We believe that the difficulties facing some parts of the pharmaceutical industry will result in greater use of such tools as managers realize that the savings in time and money that can be achieved through their application vastly exceeds the cost of obtaining and learning to use them.”